LH expands specialty testing, acquisitions and AI initiatives to drive growth, but macro pressures and currency headwinds ...

The nationwide rollout, which Labcorp disclosed Monday, comes weeks after the Centers for Medicare and Medicaid Services approved coverage for ColoSense, and the American Cancer Society named the test ...

A healthcare company is preparing to pay $35,000,000 to settle a class action lawsuit over a cybersecurity incident that ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

ColoSense is designed for adults aged 45 to 85 years who are considered at average risk for colorectal cancer.

Laboratory Corp. of America isn’t liable for Medicaid fraud in Texas because any potential false statements it made had no impact on millions of dollars in payments it received, a split state supreme ...

Collaboration leverages Olaris' scientific leadership in transplant diagnostics and Labcorp's scientific expertise and national scale to advance post-transplant monitoring. FRAMINGHAM, Mass.

Labcorp will report third-quarter 2025 results on Oct. 28, before market open. LH's Q3 revenues are estimated at $3.56B, up 8.3%, while EPS is projected to rise 18% to $4.13. LH's Diagnostics and ...

Labcorp currently trades at $265.08 per share and has shown little upside over the past six months, posting a middling return ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min As the number of Americans at ...

Detailed price information for Laboratory Corp of America (LH-N) from The Globe and Mail including charting and trades.

View Labcorp Holdings Inc. LH stock quote prices, financial information, real-time forecasts, and company news from CNN.